Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Good afternoon, everyone. I'm Sean Laaman, Head of U.S. Mid-cap Biotech Equity Research here at Morgan Stanley, and welcome to Morgan Stanley Global Healthcare Conference. Before we commence, to make you aware of some important disclosures, please go to the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have the pleasure of hosting from Eikon Therapeutics, their CEO, Roger Perlmutter; and CFO, Freddie Bowie. Thank you, gentlemen, for attending and look forward to the discussion.

Thank you, Sean. Appreciate it.

Thank you for having us.

And thanks for doing this. I've got a couple of macro questions to begin with. So let's just punch through them and get to the meat, which is Eikon. Okay. So how is the rise of China-originated innovation changing, if at all, your competitive positioning in your R&D and BD playbook?

Well, I think that the rise of China has affected everybody in the industry, of course. I see that as a natural evolution. This has been going on for a very long time. 25 years ago, we watched as a flood of very high-quality Chinese graduate students made their way to the United States, and were studying in American laboratories and or even more, even further ago than that. And it's only natural that many of those people, well trained, experienced, decided there were opportunities in